Minhwa Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Minhwa Park has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- So-Youn Woo
Department of Microbiology, College of Medicine, Ewha Womans University, Seoul, Korea
4 shared publications - Yu-Hee Kim
Advanced Biomedical Research Institute, Ewha Womans University Seoul Hospital, Seoul, South Korea
4 shared publications - Kyung-Ha Ryu
Department of Pediatrics, College of Medicine, Ewha Womans University, Seoul, Republic of Korea
3 shared publications - Jung-Hwa Ryu
Department of Microbiology, School of Medicine, Ewha Womans University, Seoul 158-710, Republic of Korea
2 shared publications - Da-Won Choi
Department of Microbiology, College of Medicine, Ewha Womans University, Seoul 07804, Korea
1 shared publication Han Su Kim
Department of Otolaryngology, College of Medicine, Ewha Womans University, Seoul 07985, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by XMLink in Annals of Dermatology
- Vol. 33 (5) , 402-408
Toll-Like Receptor 7 (TLR7) Mediated Transcriptomic Changes on Human Mast Cells
Cho KA, et al. Ann Dermatol. 2021 Oct;33(5):402-408. https://doi.org/10.5021/ad.2021.33.5.402
- 1 January 2021
- Published by XMLink in Annals of Dermatology
- Vol. 33 (5) , 402-408
Open AccessToll-Like Receptor 7 (TLR7) Mediated Transcriptomic Changes on Human Mast Cells
Cho KA, et al. Ann Dermatol. 2021 Oct;33(5):402-408. https://doi.org/10.5021/ad.2021.33.5.402
- Open Access
- 10 September 2019
- Published by Wiley in Stem Cells International
- Vol. 2019, 1-10
Identification of WNT16 as a Predictable Biomarker for Accelerated Osteogenic Differentiation of Tonsil-Derived Mesenchymal Stem Cells In Vitro
The application of mesenchymal stem cells (MSCs) for treating bone-related diseases shows promising outcomes in preclinical studies. However, cells that are isolated and defined as MSCs comprise a heterogeneous population of progenitors. This heterogeneity can produce variations in the performance of MSCs, especially in applications that require differentiation potential in vivo, such as the treatment of osteoporosis. Here, we aimed to identify genetic markers in tonsil-derived MSCs (T-MSCs) that can predict osteogenic potential. Using a single-cell cloning method, we isolated and established several lines of nondifferentiating (ND) or osteoblast-prone (OP) clones. Next, we performed transcriptome sequencing of three ND and three OP clones that maintained the characteristics of MSCs and determined the top six genes that were upregulated in OP clones. Upregulation of WNT16 and DCLK1 expression was confirmed by real-time quantitative PCR, but only WNT16 expression was correlated with the osteogenic differentiation of T-MSCs from 10 different donors. Collectively, our findings suggest that WNT16 is a putative genetic marker that predicts the osteogenic potential of T-MSCs. Thus, examination of WNT16 expression as a selection criterion prior to the clinical application of MSCs may enhance the therapeutic efficacy of stem cell therapy for bone-related complications, including osteoporosis.
- 10 September 2019
- Published by Wiley in Stem Cells International
- Vol. 2019, 1-10
Open AccessIdentification of WNT16 as a Predictable Biomarker for Accelerated Osteogenic Differentiation of Tonsil-Derived Mesenchymal Stem Cells In Vitro
The application of mesenchymal stem cells (MSCs) for treating bone-related diseases shows promising outcomes in preclinical studies. However, cells that are isolated and defined as MSCs comprise a heterogeneous population of progenitors. This heterogeneity can produce variations in the performance of MSCs, especially in applications that require differentiation potential in vivo, such as the treatment of osteoporosis. Here, we aimed to identify genetic markers in tonsil-derived MSCs (T-MSCs) that can predict osteogenic potential. Using a single-cell cloning method, we isolated and established several lines of nondifferentiating (ND) or osteoblast-prone (OP) clones. Next, we performed transcriptome sequencing of three ND and three OP clones that maintained the characteristics of MSCs and determined the top six genes that were upregulated in OP clones. Upregulation of WNT16 and DCLK1 expression was confirmed by real-time quantitative PCR, but only WNT16 expression was correlated with the osteogenic differentiation of T-MSCs from 10 different donors. Collectively, our findings suggest that WNT16 is a putative genetic marker that predicts the osteogenic potential of T-MSCs. Thus, examination of WNT16 expression as a selection criterion prior to the clinical application of MSCs may enhance the therapeutic efficacy of stem cell therapy for bone-related complications, including osteoporosis.
- Open Access
- 5 March 2019
- Published by Wiley in Stem Cells International
- Vol. 2019, 1
Corrigendum to “Immune Suppressive Effects of Tonsil-Derived Mesenchymal Stem Cells on Mouse Bone-Marrow-Derived Dendritic Cells”
[This corrects the article DOI: 10.1155/2015/106540.].
- 5 March 2019
- Published by Wiley in Stem Cells International
- Vol. 2019, 1
Open AccessCorrigendum to “Immune Suppressive Effects of Tonsil-Derived Mesenchymal Stem Cells on Mouse Bone-Marrow-Derived Dendritic Cells”
[This corrects the article DOI: 10.1155/2015/106540.].
- Open Access
- 16 February 2015
- Published by Hindawi Limited in Stem Cells International
- Vol. 2015, 1-12
Immune Suppressive Effects of Tonsil-Derived Mesenchymal Stem Cells on Mouse Bone-Marrow-Derived Dendritic Cells
Mesenchymal stem cells (MSCs) are considered valuable sources for cell therapy because of their immune regulatory function. Here, we investigated the effects of tonsil-derived MSCs (T-MSCs) on the differentiation, maturation, and function of dendritic cells (DCs). We examined the effect of T-MSCs on differentiation and maturation of bone-marrow- (BM-) derived monocytes into DCs and we found suppressive effect of T-MSCs on DCs via direct contact as well as soluble mediators. Moreover, T cell proliferation, normally increased in the presence of DCs, was inhibited by T-MSCs. Differentiation of CD4+T cell subsets by the DC-T cell interaction also was inhibited by T-MSCs. The soluble mediators suppressed by T-MSCs were granulocyte-macrophage colony-stimulating factor (GM-CSF), RANTES, interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1). Taken together, T-MSCs exert immune modulatory function via suppression of the differentiation, maturation, and function of BM-derived DCs. Our data suggests that T-MSCs could be used as a novel source of stem cell therapy as immune modulators.
- 16 February 2015
- Published by Hindawi Limited in Stem Cells International
- Vol. 2015, 1-12
Open AccessImmune Suppressive Effects of Tonsil-Derived Mesenchymal Stem Cells on Mouse Bone-Marrow-Derived Dendritic Cells
Mesenchymal stem cells (MSCs) are considered valuable sources for cell therapy because of their immune regulatory function. Here, we investigated the effects of tonsil-derived MSCs (T-MSCs) on the differentiation, maturation, and function of dendritic cells (DCs). We examined the effect of T-MSCs on differentiation and maturation of bone-marrow- (BM-) derived monocytes into DCs and we found suppressive effect of T-MSCs on DCs via direct contact as well as soluble mediators. Moreover, T cell proliferation, normally increased in the presence of DCs, was inhibited by T-MSCs. Differentiation of CD4+T cell subsets by the DC-T cell interaction also was inhibited by T-MSCs. The soluble mediators suppressed by T-MSCs were granulocyte-macrophage colony-stimulating factor (GM-CSF), RANTES, interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1). Taken together, T-MSCs exert immune modulatory function via suppression of the differentiation, maturation, and function of BM-derived DCs. Our data suggests that T-MSCs could be used as a novel source of stem cell therapy as immune modulators.